Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of medicine for preventing and/or treating pulmonary fibrosis

A technology for pentagalloyl glucose and pulmonary fibrosis, which is applied in the field of medicine and can solve problems that have not yet been treated

Active Publication Date: 2021-05-18
GUANGZHOU SHENGPU INVESTMENT MANAGEMENT
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] 1,2,3,4,6-O-Pentagalloyl Glucose (PGG) is the representative of natural ellagitannin, which belongs to the hydrolysis product of tannin, and naturally exists in various plants such as salt bran, peony, geranium, etc. It has various physiological activities such as inhibiting biological enzymes, antibacterial, antiviral, anti-inflammatory, anticancer, antidiabetic, antiplatelet, etc., but there is no research on its treatment of diseases related to pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of medicine for preventing and/or treating pulmonary fibrosis
  • Application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of medicine for preventing and/or treating pulmonary fibrosis
  • Application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of medicine for preventing and/or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Inhibitory Effect of 1,2,3,4,6-O-Pentagalloyl Glucose on the Proliferation of Lung Fibroblasts

[0073] 1. Experimental method

[0074] Lung fibroblasts were purchased from Fenghui Biocell Company.

[0075] (1) Cell culture

[0076] Lung fibroblasts were cultured in high-glucose DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and glucose concentration 4.5g / L, and the cells were placed at 37°C with 5% CO 2 Incubator, replace the cell culture medium every 2 days. When the cell density was 80%-90%, the cells were digested with trypsin and resuspended for passage.

[0077] (2) Administration

[0078] After observing that the cells were growing well, the cells were digested and resuspended, and the fibroblasts were seeded on a black 96-well plate at a density of 3000 cells per well. 24 hours after cell seeding, add TGF-β at a concentration of 10 ng / mL to each well 1 , to establish a cellular lung fibrosis model. After culturing...

Embodiment 2

[0090] Example 2 1,2,3,4,6-O-pentagalloyl glucose anti-pulmonary fibrosis experiment

[0091] 1. Experimental method

[0092] (1) SPF grade Wistar rats were randomly divided into 5 groups according to body weight, 30 rats in each group. They were sham operation group, model group, 1,2,3,4,6-O-pentagalloyl glucose high dose (500mg / (kg·d)), medium dose (250mg / (kg·d)) and low dose Dosage group (125mg / (kg·d)).

[0093] (2) Model preparation

[0094] After the experimental animals were purchased, they were reared routinely and adapted to the environment for 7 days. During the experiment, the animals were anesthetized by intraperitoneal injection of 3 mL / kg of 10% chloral hydrate, made to lie supine and fixed on the mouse board, and the hair on the neck was clipped. The skin was routinely disinfected, and a mid-neck incision about 0.5-1 cm in length was made under aseptic operation. Peel off the exposed trachea layer by layer, and then raise the head of the mouse board so that ...

Embodiment 3

[0103] Example 3 1,2,3,4,6-O-pentagalloyl glucose acute toxicity test

[0104] 1. Experimental method

[0105] The acute toxicity maximum tolerated dose method was used for the test. Set up a blank group and a 1,2,3,4,6-O-pentagalloyl glucose (1.5g / mL) group, a total of 2 groups, select 60 quarantine-qualified SPF-grade ICR mice, half male and half female, press Gender and body weight were randomly divided into two groups with 30 rats in each group, fasting for more than 12 hours before administration, no administration in the blank group, and 0.4ml / 10g in the drug group during the test. 体重 Perform one-time gavage administration. On the day of administration, especially within 0-4 hours after administration, closely observe and record the poisoning manifestations and characteristics, occurrence and recovery time of toxic reactions, and death of animals in each group. Then observe twice a day, that is, once in the morning and once in the afternoon, and observe continuously f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of 1, 2, 3, 4, 6-O-pentagalloylglucose (PGG) in preparation of a medicine for preventing and / or treating pulmonary fibrosis. The invention initiatively discovers that PGG has a good treatment effect on pulmonary fibrosis and does not have any adverse reaction, a new choice is provided for a medicine for treating pulmonary fibrosis, a natural novel medicine source is provided for treatment of pulmonary fibrosis diseases, and the medicine is efficient, safe and free of toxic or side effect.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of 1,2,3,4,6-O-pentagalloyl glucose in the preparation of drugs for preventing and / or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by fibroblast proliferation and accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction, that is, normal alveolar tissue is damaged and undergoes abnormal repair to lead to structural changes. Abnormal (scarring). The cause of most patients with pulmonary fibrosis is unknown (idiopathic). This group of diseases is called idiopathic interstitial pneumonia (IIP), which is a large category of interstitial lung diseases. Among idiopathic interstitial pneumonia (IIP), the most common disease type with pulmonary fibrosis as the main manifestation is idi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61K9/08A61K9/20A61K9/48A61K9/12A61K47/10A61K47/22A61K47/36A61K47/38A61P11/00A23L33/125
CPCA61K31/7034A61K9/0095A61K47/10A61K9/2059A61K9/4866A61K9/12A61K9/0073A61K47/22A61P11/00A23L33/125A23V2002/00A23V2200/314
Inventor 付军
Owner GUANGZHOU SHENGPU INVESTMENT MANAGEMENT